Ryan Ghusayni, MD
Neurology · Raleigh, NCNPI 1245736222
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $731 and has fallen 56.6% since, to $317 in 2025.
Across 48 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$255
- Argenx US, Inc.$191
- Johnson & Johnson$100
- AstraZeneca$98
- Grifols USA, LLC$53
- TG Therapeutics, Inc.$51
- plus $402 from 15 others
What the payments were for
- Food & beverage$1,06693%
- Education$847%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 7 | $255 |
| Argenx US, Inc. | 9 | $191 |
| Johnson & Johnson | 2 | $100 |
| AstraZeneca | 4 | $98 |
| Grifols USA, LLC | 2 | $53 |
| TG Therapeutics, Inc. | 2 | $51 |
| AbbVie | 2 | $42 |
| Bristol Myers Squibb | 2 | $40 |
| Lundbeck LLC | 2 | $39 |
| Harmony Biosciences LLC | 2 | $35 |
| Lilly USA, LLC | 2 | $32 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Aucta Pharmaceuticals, Inc. | 2 | $30 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Impel Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,150 in reported general payments places this provider in the 55th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 34 | $25,701 |
| Nurtec OdtRimegepant Sulfate | 11 | $18,309 |
| Lacosamide | 25 | $3,143 |
| Pyridostigmine Bromide | 12 | $1,977 |
| Memantine Hcl | 119 | $1,645 |
| RivastigmineRivastigmine Tartrate | 23 | $1,414 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 91 | $1,410 |
| Donepezil Hcl | 89 | $1,106 |
| Gabapentin | 48 | $1,104 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $531 |
| Levetiracetam | 40 | $519 |
| Baclofen | 37 | $484 |
| Propranolol Hcl | 23 | $472 |
| Primidone | 19 | $278 |
| Duloxetine Hcl | 17 | $263 |
Paid to pharmacies, not to this prescriber.
Other neurology in Raleigh
- John ScagnelliRaleigh$429K
- Timothy RyanRaleigh$85K
- Casey JeffreysRaleigh$82K
- Sommer PhilipsRaleigh$46K
- Steven FreedmanRaleigh$42K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.